Abstract
Objectives To describe the point prevalence of SARS-CoV-2 in care homes reporting low numbers of cases of COVID-19.
Design A cross-sectional study of care homes, ascertaining perceived disease burden using interviews with care home managers and SARS-CoV-2 RNA detection in residents and staff using nose and throat swabbing.
Setting 15 Care homes in Essex, United Kingdom, all of which had reported either zero or one case of COVID-19 to the Health Protection Team.
Participants 912 residents and staff of care homes were tested. Residents were eligible to be tested regardless of symptoms.
Main outcome measure Detection of SARS-CoV-2 in residents and staff.
Results In the 15 care homes studied, SARS-CoV-2 was detected in 23 (5.2%) of 441 residents. Of these 23, 21/23 (91%) were asymptomatic as reported by the care home managers. SARS-CoV-2 was detected in 8/471 (1.7%) of staff. This differs from that in residents (p=0.003).
Conclusions The study’s findings suggest that symptoms, as reported by care home managers, are an insensitive method of defining the extent of SARS-CoV-2 infection in nursing homes. Viral detection from residents is more common than from staff. Microbiological screening is a more sensitive method for defining the extent of SARS-CoV-2 in care homes than managerial reporting of resident symptoms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been subject to an internal ethical and governance review at Public Health England which considered the study design, content and feasibility. The review also covered all legal, financial, regulatory and ethical considerations. As a result of this review, the study was categorized as a public health practice study that was being undertaken to help to manage the COVID 19 outbreak. As no ethical issues were identified it was decided that consideration by an ethics committee would not be necessary. PHE reference: NR0226 Please see letter from PHE attached in the supplemental files.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
annastarling{at}nhs.net
Data Availability
Non-identifiable patient data is available on request.
